Why the study?
Doxorubicin causes notable cardiotoxicity involving pyroptosis, and it was unclear whether ticagrelor exerts non-platelet pharmacological effects on this process via GSK-3β.
Does ticagrelor reduce doxorubicin-induced pyroptosis in rat cardiomyocytes?
Population
Rats, rat cardiac myocytes, and rat embryonic cardiac-derived H9c2 cells
Comparison
Ticagrelor pretreatment before doxorubicin vs doxorubicin alone
Design
Preclinical in vivo and in vitro animal and cell study
Follow-up
8 weeks after the last administration
Authors
Loading...
Hypothesis-generating for ticagrelor in doxorubicin cardiotoxicity; leaves open human translation and requires prospective trials.
Does ticagrelor reduce doxorubicin-induced pyroptosis in rat cardiomyocytes?
Ticagrelor mitigates doxorubicin-induced cardiotoxicity and pyroptosis in rat models via the GSK-3β/caspase-1 pathway, suggesting a potential novel pharmacological benefit.
Wang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: